article thumbnail

$2 billion mRNA-based oncology therapy market anticipated by 2029

European Pharmaceutical Review

The global mRNA-based oncology therapy market is expected to reach $2 billion by 2029, according to GlobalData. percent share by 2029, the research has shown. percent of the total mRNA therapy market by 2029. BioNTech is anticipated to lead the market with a predicted $885 million in sales, and a 44.6

Marketing 110
article thumbnail

Biopharma sees strong Q2 2023 market cap growth

European Pharmaceutical Review

billion sales globally by 2029, this could offset Keytruda’s decline sales expected after its loss of exclusivity in 2028, GlobalData highlighted. This is mainly due to the reported decline in sales of Humira, a consequence of biosimilar competition. With the company’s monoclonal antibody drug candidate PRA023 predicted to reach $2.1

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

EHA 2023: Kura Oncology’s menin inhibitor ziftomenib shows impressive Phase I results

Pharmaceutical Technology

According to GlobalData’s analyst consensus forecast, global sales for ziftomenib will reach $255m by 2029. Kura faces competition in the menin inhibitor market as the therapy is being developed to treat various indications. GlobalData forecasts total sales from this drug class to exceed $1bn by 2029.

article thumbnail

Merck defends blockbuster Januvia franchise from patent challenge

pharmaphorum

Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug for another few years. 8,414,921), which covers the co-formulation of sitagliptin and metformin and is due to expire in 2029.

article thumbnail

NICE recommends AbbVie’s/J&J’s Imbruvica for combo use in untreated CLL

Pharmaceutical Technology

While Imbruvica maintained a previously strong position on the market, competition has chipped away at the inhibitor’s market share. billion in 2029, while Calquence is expected to make $5.31 billion in 2029, while Calquence is expected to make $5.31 billion in 2029. billion in the same year. billion in the same year.

article thumbnail

Sustainability and technology advancement driving spectroscopy market

European Pharmaceutical Review

Their report ascertained that growth between 2019-2024 resulted from factors such as quality control demands, cost efficiency, rapid analysis, market competition, healthcare innovations. billion in 2029 at a compound annual growth rate (CAGR) of 7.9 It will grow to $31.77

article thumbnail

Key Developments from AMCP 2023 on Blockbuster Generics, Diabetes Drugs, PBM Legislation, and More

PM360

Attention deficit hyperactivity disorder (ADHD) drug Vyvanse (lisdexamfetamine dimesylate) , manufactured by Takeda, also is facing generic competition. In the respiratory area with inhalers, it’s tough to get drugs approved, so the competition comes slowly,” he said. Starting in 2026, the provision will affect 10 Part D drugs.